FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall St slumps as sharp tech losses put Nasdaq on course for correction
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
BTIG Reiterates Buy Rating on Innate Pharma S.A. (IPHA)
Tweet Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $9.00 price target on Innate Pharma S.A. (NASDAQ: IPHA).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
